Subcutaneous vs Intravenous Administration of CT-P13 for Rheumatoid Arthritis: Part 2 of Randomized Phase I/III Trial

Source: Clinical Impact of New Rheumatoid Arthritis Data from APLAR 2019, JCR 2019, and EULAR 2019*
Download Slideset
APLAR 2019: Brisbane, Australia; April 8-11, 2019; JCR: Kyoto, Japan; April 15-17, 2019
EULAR: Madrid, Spain; June 12-15, 2019
SC formulation of CT-P13 demonstrated noninferior efficacy compared to IV formulation for change in DAS28-CRP from baseline to Week 22 in patients with rheumatoid arthritis.
Format: Microsoft PowerPoint (.ppt)
File Size: 202 KB
Released: June 21, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo
Contact Info

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Gilead Sciences
Lilly
Sanofi Genzyme and Regeneron Pharmaceuticals

Related Content

Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.

Released: December 23, 2020

From ACR/ARP 2020: expert-authored commentary on tapering RA therapy, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 18, 2020 Expired: December 17, 2021

Safety: Frequently asked questions from the CCO Webinar series, “ A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis”

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: December 18, 2020

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 18, 2020 Expired: December 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue